Incannex Healthcare Limited Sponsored ADR (IXHL)
NASDAQ:IXHL
Want to see IXHL full AI Analyst Report?
IXHL Stock Chart & Stats
$0.39
-$0.11(-5.37%)
At close: 4:00 PM EST
$0.39
-$0.11(-5.37%)
Day’s Range― - ―
52-Week Range$2.49 - $49.80
Previous CloseN/A
Volume10.98K
Average Volume (3M)289.73K
Market Cap
$42.59M
Enterprise Value-$30.07M
Total Cash (Recent Filing)$68.90M
Total Debt (Recent Filing)$163.00K
Price to Earnings (P/E)―
Beta3.72
Next Earnings
Sep 02, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.29
Shares Outstanding11,964,554
10 Day Avg. Volume396,985
30 Day Avg. Volume289,728
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.55
Price to Sales (P/S)86.40
P/FCF Ratio-0.59
Enterprise Value/Market Cap-0.71
Enterprise Value/Revenue-451.35
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.66
Forecast
1Y Price Target
$18.00Price Target Upside4515.38% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.75
Revenue Forecast (FY)$700.00K
Bulls Say, Bears Say
Bulls Say
Strong Cash Position, No DebtA cash balance of roughly $75M with no debt materially strengthens financing flexibility for the next 2–6 months and beyond. It funds the DReAMzz Phase 2 program, reduces immediate dilution pressure, and permits selective buybacks or opportunistic investment in pivotal trials.
Material Non-dilutive R&D FundingSecuring over A$11.1M in R&D tax incentive proceeds provides non-dilutive capital that meaningfully extends runway for clinical programs. This funding reduces near-term financing reliance, underwrites trial costs, and distinguishes the company from peers that must issue equity to fund development.
Clinical Momentum And Regulatory SupportAdvancing IHL-42X into a dose-optimization DReAMzz study, backed by Phase 2 efficacy and Fast Track status, lowers clinical risk and clarifies a Phase 3 pathway. Sustained program progress and external recognition strengthen commercialization prospects in a large, underserved sleep apnea market.
Bears Say
Persistent Negative Free Cash FlowConsistent negative operating and free cash flow (~-$12.5M in 2025) indicates the business consumes cash to operate and develop assets. This structural burn necessitates continued access to external capital until revenue scales or approvals are achieved, creating execution and dilution risk.
Deep Ongoing Losses And Weak MarginsThe company remains in a heavy loss-making phase with deeply negative operating and net margins, preventing returns on equity. Without commercial revenues from approved products, profitability is uncertain and investor returns depend on successful late-stage trials and market adoption, which take time.
Dependence On Capital Markets For FundingThe history of large ATM proceeds, termination of that facility, and a $10M direct offering highlight reliance on equity financings to fund R&D. Even with current cash, ongoing development may require further market access, exposing shareholders to dilution and timing risk until commercial cash flow emerges.
Incannex Healthcare Limited Sponsored ADR News
IXHL FAQ
What was Incannex Healthcare Limited Sponsored ADR’s price range in the past 12 months?
Incannex Healthcare Limited Sponsored ADR lowest stock price was $2.49 and its highest was $49.80 in the past 12 months.
What is Incannex Healthcare Limited Sponsored ADR’s market cap?
Incannex Healthcare Limited Sponsored ADR’s market cap is $42.59M.
When is Incannex Healthcare Limited Sponsored ADR’s upcoming earnings report date?
Incannex Healthcare Limited Sponsored ADR’s upcoming earnings report date is Sep 02, 2026 which is in 73 days.
How were Incannex Healthcare Limited Sponsored ADR’s earnings last quarter?
Incannex Healthcare Limited Sponsored ADR released its earnings results on Mar 02, 2026. The company reported -$0.6 earnings per share for the quarter, the consensus estimate of -$0.6 by $0.
Is Incannex Healthcare Limited Sponsored ADR overvalued?
According to Wall Street analysts Incannex Healthcare Limited Sponsored ADR’s price is currently Undervalued.
Does Incannex Healthcare Limited Sponsored ADR pay dividends?
Incannex Healthcare Limited Sponsored ADR does not currently pay dividends.
What is Incannex Healthcare Limited Sponsored ADR’s EPS estimate?
Incannex Healthcare Limited Sponsored ADR’s EPS estimate is -0.14.
How many shares outstanding does Incannex Healthcare Limited Sponsored ADR have?
Incannex Healthcare Limited Sponsored ADR has 11,964,554 shares outstanding.
What happened to Incannex Healthcare Limited Sponsored ADR’s price movement after its last earnings report?
Incannex Healthcare Limited Sponsored ADR reported an EPS of -$0.6 in its last earnings report, expectations of -$0.6. Following the earnings report the stock price went down -9.906%.
Which hedge fund is a major shareholder of Incannex Healthcare Limited Sponsored ADR?
Currently, no hedge funds are holding shares in IXHL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Incannex Healthcare Limited Sponsored ADR Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$18.00 (4515.38% Upside)
$18.00 (4515.38% Upside)
Blogger Sentiment
Bullish
IXHL Sentiment 70%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 2.1%
Last 30 Days ▼ 2.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-46.90%
12-Months-Change
Fundamentals
Return on Equity
-122.57%
Trailing 12-Months
Asset Growth
395.67%
Trailing 12-Months
Company Description
Incannex Healthcare Limited Sponsored ADR
Incannex Healthcare Limited is an Australian company dedicated to the research, development, and commercialization of medicinal cannabinoid products. The firm offers pharmaceutical-grade cannabinoid compounds under its proprietary Incannex brand. Its product pipeline includes several key assets: IHL-42X: This compound is currently undergoing Phase II clinical evaluation for the treatment of obstructive sleep apnea (OSA). Incannex partners with The Alfred Hospital and Novotech on this specific clinical program. IHL-216A: Designed to address traumatic brain injury (TBI). Furthermore, the Monash Trauma Group, part of Monash University's Department of Neuroscience, is conducting a study on IHL-216A's protective effects against sports-related concussions. IHL-675A: A unique formulation combining hydroxychloroquine and cannabidiol, developed for both the prevention and management of a range of inflammatory conditions. These include acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease (COPD), asthma, bronchitis, rheumatoid arthritis, and inflammatory bowel diseases. Originally established in 2001 as Impression Healthcare Limited, the company officially changed its name to Incannex Healthcare Limited in June 2020. Incannex maintains its corporate headquarters in Sydney, Australia.
IXHL Stock 12 Month Forecast
Average Price Target
$18.00
▲(4515.38% Upside)
Technical Analysis
―
Cumberland Pharmaceuticals
―
China SXT Pharmaceuticals
―
Journey Medical Corp
―
BioAge Labs, Inc.
―
Ownership Overview
Currently, No data available
---